Synact Pharma
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
SynAct Pharma AB is a clinical stage biotechnology company focused on developing novel resolution therapies for inflammatory diseases. Lead program, Resomelagon, Phase 2b in rheumatoid arthritis, is a potential first-in-class novel non-suppressive therapeutic opportunity that enables key immune cell modulation to reduce inflammatory activity and promote resolution.
Resomelagon in development for autoimmune diseases (lead indication: rheumatoid arthritis) and host-directed therapy in viral infections with potential to support millions of patients globally.
Company HQ City:
Holte
Company HQ State:
Capital region
Company HQ Country:
Denmark
Year Founded:
2012
Lead Product in Development:
Resomelagon (AP-1189)
CEO
CEO: Jeppe Oevlesen
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
One (1)
Exchange
Nasdaq
Ticker
SYNACT
When you expect your next catalyst update?
Jan/Feb: Last patient first visit;
Jun: topline results
What is your next catalyst (value inflection) update?
Phase 2b data expected very close the Bio meeting
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}